Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 132, Issue 25
December 20 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

Hematopoiesis and Stem Cells
PU.1 chromosomal dynamics are linked to LDB1
Ann Dean
View Articletitled, PU.1 chromosomal dynamics are linked to LDB1
Lymphoid Neoplasia
Nuclear Fox(O1): not so fantastic
Marc A. Weniger
View Articletitled, Nuclear Fox(O1): not so fantastic

PERSPECTIVE

Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?
CME Clinical Trials & Observations
Scott J. Cameron,Hannah M. Russell,A. Phillip Owens, III
View Articletitled, Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?

CLINICAL TRIALS AND OBSERVATIONS

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
Clinical Trials & Observations
Michael Dickinson,on behalf of the SUPPORT study investigators,Honar Cherif,on behalf of the SUPPORT study investigators,Pierre Fenaux,on behalf of the SUPPORT study investigators,Moshe Mittelman,on behalf of the SUPPORT study investigators,Amit Verma,on behalf of the SUPPORT study investigators,Maria Socorro O. Portella,on behalf of the SUPPORT study investigators,Paul Burgess,on behalf of the SUPPORT study investigators,Pedro Marques Ramos,on behalf of the SUPPORT study investigators,Jeea Choi,on behalf of the SUPPORT study investigators,Uwe Platzbecker,on behalf of the SUPPORT study investigators
View Articletitled, Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
Supplemental data
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Clinical Trials & Observations Brief Report
Craig H. Moskowitz,Jan Walewski,Auayporn Nademanee,Tamas Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick Stiff,Simonetta Viviani,Veronika Bachanova,Anna Sureda,Teresa McClendon,Connie Lee,Julie Lisano,John Sweetenham
View Articletitled, Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

HEMATOPOIESIS AND STEM CELLS

Temporal autoregulation during human PU.1 locus SubTAD formation
Daniel Schuetzmann,Carolin Walter,Boet van Riel,Sabrina Kruse,Thorsten König,Tabea Erdmann,Alexander Tönges,Eric Bindels,Andre Weilemann,Claudia Gebhard,Klaus Wethmar,Chiara Perrod,Julia Minderjahn,Michael Rehli,Ruud Delwel,Georg Lenz,Stefan Gröschel,Martin Dugas,Frank Rosenbauer
View Articletitled, Temporal autoregulation during human PU.1 locus SubTAD formation
Supplemental data

LYMPHOID NEOPLASIA

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
Patricia Gomez-Bougie,Sophie Maiga,Benoît Tessoulin,Jessie Bourcier,Antoine Bonnet,Manuel S. Rodriguez,Steven Le Gouill,Cyrille Touzeau,Philippe Moreau,Catherine Pellat-Deceunynck,Martine Amiot
View Articletitled, BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
Supplemental data
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells
Eleni Kabrani,Van Trung Chu,Evangelia Tasouri,Thomas Sommermann,Kevin Baßler,Thomas Ulas,Thorsten Zenz,Lars Bullinger,Joachim L. Schultze,Klaus Rajewsky,Sandrine Sander
View Articletitled, Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells
Supplemental data

LETTER TO BLOOD

Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score
Clinical Trials & Observations
Amaris K. Balitsky,John G. Kelton,Donald M. Arnold
View Articletitled, Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score
CREBBP gene mutations are frequently detected in in situ follicular neoplasia
Janine Schmidt,Joan Enric Ramis-Zaldivar,Irina Bonzheim,Julia Steinhilber,Inga Müller,Andrea Haake,Shan Chi Yu,Mark Raffeld,Falko Fend,Itziar Salaverria,Reiner Siebert,Elaine S. Jaffe,Leticia Quintanilla-Martinez
View Articletitled, <em>CREBBP</em> gene mutations are frequently detected in in situ follicular neoplasia
Supplemental data
Chronic Borrelia burgdorferi infection triggers NKT lymphomagenesis
Rémy Robinot,Emmanuel Bachy,Sammara Chaubard,Mirjam Urb,Sylvain Carras,Emilie Bardel,Dimitri Chartoire,Alexandra Traverse-Glehen,Patrice N. Marche,Gilles Salles,Benoit Jaulhac,Laurent Genestier
View Articletitled, Chronic <em>Borrelia burgdorferi</em> infection triggers NKT lymphomagenesis
Supplemental data
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms
Cristina Mambet,Olga Babosova,Jean-Philippe Defour,Emilie Leroy,Laura Necula,Oana Stanca,Aurelia Tatic,Nicoleta Berbec,Daniel Coriu,Monika Belickova,Barbora Kralova,Lucie Lanikova,Jitka Vesela,Christian Pecquet,Pascale Saussoy,Violaine Havelange,Carmen C. Diaconu,Vladimir Divoky,Stefan N. Constantinescu
View Articletitled, Cooccurring <em>JAK2</em> V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms
Supplemental data

BLOOD WORK

Idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobinemia mimicking plasma cell myeloma
Chih-Chieh Yen,Tsai-Yun Chen
View Articletitled, Idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobinemia mimicking plasma cell myeloma

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Antithrombotic therapy in AAA
CME
View Articletitled, Antithrombotic therapy in AAA
  • Cover Image

    Cover Image

    issue cover

    Immunofluorescence staining for FOXO1 expression in murine Burkitt lymphoma (BL) cells (FOXO1 is shown in red; DAPI [4′,6-diamidino-2-phenylindole] labels the nuclei blue). Although phosphoinositide-3-kinase signaling is constantly active in BL cells, FOXO1 escapes nuclear exclusion by gaining genomic mutations. Importantly, proliferation and survival are promoted by nuclear FOXO1 in BL. See the article by Kabrani et al on page 2670.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Licking the wound with procoagulant vesicles
Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study
CAR T-cells in autoimmunity: game changer or stepping stone?
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals